Loading...
Bilateral Trade Intelligence · $27.6M Total Trade · 21 Foreign Suppliers · 18 Indian Buyers · DGFT Verified · Updated March 2026
India imported $27.6M worth of pharmaceutical formulations from Malta across 721 verified shipments, from 21 foreign suppliers to 18 Indian buyers. The top suppliers are ACTAVIS LIMITED ($27.2M) and PFIZER ($286.0K). The leading products are Telmisartan ($18.5M) and Ezetimibe ($3.0M). Average shipment value: $38.3K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Telmisartan | $18.5M | 67.2% |
| 2 | Ezetimibe | $3.0M | 10.9% |
| 3 | Simvastatin | $3.0M | 10.9% |
| 4 | Ofloxacin | $717.7K | 2.6% |
| 5 | Levofloxacin | $717.7K | 2.6% |
| 6 | Enalapril | $658.8K | 2.4% |
| 7 | Ramipril | $520.7K | 1.9% |
| 8 | Lenalidomide | $286.0K | 1.0% |
| 9 | Glimepiride | $43.6K | 0.2% |
| 10 | Clopidogrel | $13.1K | 0.0% |
| 11 | Amlodipine | $12.6K | 0.0% |
| 12 | Citalopram | $9.8K | 0.0% |
| 13 | Escitalopram | $9.8K | 0.0% |
| 14 | Atorvastatin | $9.3K | 0.0% |
| 15 | Terbinafine | $7.7K | 0.0% |
India imports 20+ pharmaceutical formulations from Malta with a combined trade value of $27.6M. Key products include Telmisartan ($18.5M), Ezetimibe ($3.0M), Simvastatin ($3.0M), Ofloxacin ($718K), Levofloxacin ($718K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 721 verified Indian Customs (DGFT) shipment records.
India exported pharmaceuticals worth $27.6M to Malta across 721 verified shipments.
1. ACTAVIS LIMITED — $27.2M. 2. PFIZER — $286.0K. 3. M/S APL SWIFT SERVICES (MALTA) LTD — $48.9K. Total: 21 suppliers.
1. ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED — $27.2M. 2. PFIZER LIMITED — $286.0K. 3. AUROBINDO PHARMA LTD — $48.8K. 18 buyers total.
1. Telmisartan ($18.5M, 67.2%); 2. Ezetimibe ($3.0M, 10.9%); 3. Simvastatin ($3.0M, 10.9%); 4. Ofloxacin ($717.7K, 2.6%); 5. Levofloxacin ($717.7K, 2.6%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $27.6M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
These are the top pharmaceutical products exported from India to Malta, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Malta buyers, regulatory requirements, and logistics for that specific product corridor. Products include Telmisartan ($18.5M), Ezetimibe ($3.0M), Simvastatin ($3.0M), Ofloxacin ($718K), Levofloxacin ($718K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
21 Indian pharmaceutical companies export finished formulations to Malta. Leading exporters include Actavis Limited, Pfizer, M/s Apl Swift Services (malta) Ltd, Actavis Limited,. The top exporter accounts for 98.6% of total India–Malta pharma exports. Source: Indian Customs (DGFT).
18 companies in Malta import pharmaceutical formulations from India. Top buyers include Actavis Pharma Development Centre Private Limited, Pfizer Limited, Aurobindo Pharma Ltd, Actavis Pharma Development Centre Pvt Ltd. The largest buyer accounts for 98.7% of India–Malta pharma imports. Source: Indian Customs (DGFT).
$38.3K per consignment across 721 shipments.
21 Indian companies. Largest: ACTAVIS LIMITED with $27.2M.
TransData Nexus covers 21 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 721 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
21 Exporters
18 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists